The Oxford Nanopore share price soared at its IPO. Should I buy now or wait?

Paul Summers takes a closer look at the post-IPO performance of Oxford Nanopore Technologies plc (LON:ONT).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3D Word IPO with Target on Chalkboard Background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

As a Fool keen to tap into long-term investment trends, I’m bullish on the outlook for the biotech sector. As such, I’ve been closely following the performance of the Oxford Nanopore (LSE: ONT) share price since the company’s highly successful IPO.

Should I be piling into the DNA-sequencer’s stock as soon as possible, or steering clear for now?

IPO success story

Based on trading to date, it’s easy to think the former. Such was the scale of demand, the Oxford Nanopore share price exploded to 645p from its initial IPO value of 425p on 30 September.

Should you invest £1,000 in The Biotech Growth Trust Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if The Biotech Growth Trust Plc made the list?

See the 6 stocks

Clearly, its involvement in tracking variants of Covid-19 over the last year or so has done the firm’s profile no harm at all. However, early investors also seem to think its plans to move into the applied genomics market — including areas such as agriculture and food safety — could light more fires under ONT stock in time.

Like every potential investment however, it’s worth asking what can go wrong as much as what can go right. I see two potential issues. 

#1 Post IPO sell-off. Although the initial gains have been excellent, there’s no guarantee the Oxford Nanopore share price will continue to ascend, even if the company executes its plans perfectly. Regardless of quality, traders will routinely sell up once the buzz dies down. It’s worth noting that momentum’s already stalled a little. The stock changes hands for 577p, as I type.

# The growth is priced in. With the Oxford Nanopore share price charging ahead, the company quickly boasted a market capitalisation of £5bn after its IPO. Based on the growth potential, that’s not entirely irrational. However, this is still a nascent market and ONT only generated a little over £100m in revenue last year. It’s also unprofitable, and could be for years.

Safer bet?

Considering the above, I won’t be investing in ONT just yet. Instead, I’m content to keep adding to my holding in Biotech Growth Fund (LSE: BIOG). This may seem like a rather odd decision. After all, BIOG’s share price has declined 18% over the last 12 months. 

Created with Highcharts 11.4.3Biotech Growth Trust Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

So, why BIOG over ONT?  Three reasons:

1# Safety in numbers. The Biotech Growth Trust has 87 holdings, based on its latest factsheet. Given the aforementioned volatility often seen in the sector, I reckon this diversification makes it considerably less risky than ONT.

2#Great track record. Despite performing poorly in 2021, BIOG has done admirably for investors over a longer time frame. Since September 2016 (and despite the recent sell-off), the share price has climbed 71%. If shares had been sold at the February peak, the gain would have been 145%.

3#Small-cap focus. BIOG’s preference for small-cap companies helps explain recent underperformance. Since these have the potential to grow at a far higher clip than established heavyweights, the longer-term gains should theoretically be very good indeed. What’s more, BIOG offers exposure to fast-paced players in emerging markets such as China.

Obviously, the share price could continue falling for now. Regardless of what happens in the global economy, it’s also worth noting that only a minority of biotech firms become profitable. Those relatively high ongoing fees (which holders of ONT won’t have) will need to be paid whatever happens.

As things stand though, BIOG will remain my sole biotech holding. Oxford Nanopore goes on the watchlist. I’ll reassess if/when the froth subsides.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers owns shares in Biotech Growth Trust. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing Articles

Prediction: in 12 months the under-achieving Legal & General Group share price could turn £10k into…

Harvey Jones expected better from the Legal & General share price, but he has no complaints about the FTSE 100…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

See the latest BP share price and dividend forecasts

Harvey Jones examines the outlook for the BP share price after what's been a tough year. The yield's climbed nicely…

Read more »

A GlaxoSmithKline scientist uses a microscope
Investing Articles

What are the most common FTSE 100 shares top UK investors put into a Stocks and Shares ISA?

Mark Hartley reveals the three most popular FTSE 100 shares found in Stocks and Shares ISAs — and why so…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

£10,000 invested in Greggs shares would deliver this much passive income…

Dr James Fox takes a closer look at Greggs' shares. He hasn't been a fan of the sausage roll maker…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

11% below its highs, this world-class FTSE 100 tech stock looks good value to me

Looking for a tech stock in the FTSE? This company is now one of the biggest financial data companies in…

Read more »

British Asian mother and young children enjoying exercise
Investing Articles

Here’s how my 1 year-old daughter’s SIPP could be worth almost £19m in 60 years

The SIPP provides Britons with a way to manage their retirement planning. Plus, you can open a SIPP at any…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

Consider 2 investment trusts and funds to target £160k from a £20k lump sum!

I think these investment trusts and ETFs could continue delivering double-digit annual returns through to 2035. Here's why.

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

How investors can aim to get rich and retire early by following Warren Buffett

Warren Buffett is an exceptionally successful investor, who has leveraged his knowledge and the power of compounding to create great…

Read more »